Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

11.16

Margin Of Safety %

Put/Call OI Ratio

0.33

EPS Next Q Diff

0.12

EPS Last/This Y

EPS This/Next Y

0.51

Price

8.27

Target Price

27.69

Analyst Recom

1.44

Performance Q

-48.57

Relative Volume

0.44

Beta

0.84

Ticker: KURA



21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-01-23KURA8.220.201.213309
2025-01-24KURA7.970.230.013680
2025-01-27KURA7.910.220.193898
2025-01-28KURA7.770.220.103943
2025-01-29KURA7.690.220.643962
2025-01-30KURA8.040.221.243984
2025-01-31KURA7.920.230.054022
2025-02-03KURA8.230.220.214143
2025-02-04KURA8.90.240.204489
2025-02-05KURA9.060.230.014684
2025-02-06KURA8.820.220.234745
2025-02-07KURA8.660.210.005672
2025-02-10KURA8.80.230.305202
2025-02-11KURA8.330.230.925229
2025-02-12KURA8.360.220.405202
2025-02-13KURA8.280.220.125192
2025-02-14KURA8.280.231.235221
2025-02-18KURA7.980.2412.275352
2025-02-19KURA8.30.2587.505385
2025-02-20KURA8.150.320.775743
2025-02-21KURA8.270.332.705854
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1



21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-01-23KURA8.21-15.9-100.4-2.41
2025-01-24KURA7.96-15.9-34.9-2.41
2025-01-27KURA7.91-15.9-52.0-2.41
2025-01-28KURA7.77-15.9-44.5-2.41
2025-01-29KURA7.69-15.9-50.5-2.41
2025-01-30KURA8.03-15.9-102.9-2.41
2025-01-31KURA7.93-15.9-48.5-2.41
2025-02-03KURA8.25-15.9-98.5-2.41
2025-02-04KURA8.89-15.9-122.2-2.41
2025-02-05KURA9.06-15.9-72.8-2.41
2025-02-06KURA8.82-15.9-42.1-2.41
2025-02-07KURA8.65-15.9-46.0-2.41
2025-02-10KURA8.79-15.9-71.3-2.41
2025-02-11KURA8.34-15.9-22.7-2.41
2025-02-12KURA8.36-15.9-61.5-2.41
2025-02-13KURA8.28-15.9-53.3-2.41
2025-02-14KURA8.28-15.9-57.2-2.41
2025-02-18KURA7.98-15.9-30.2-2.41
2025-02-19KURA8.29-15.9-92.2-2.41
2025-02-20KURA8.15-15.9-45.5-2.41
2025-02-21KURA8.27-15.9-71.5-2.41
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1



21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-01-23KURA-0.0016.2516.00
2025-01-24KURA-0.0016.2516.00
2025-01-27KURA-0.0016.3516.00
2025-01-28KURA-0.0016.3512.48
2025-01-29KURA-0.1916.3512.48
2025-01-30KURA-0.1916.3512.48
2025-01-31KURA-0.1916.3512.48
2025-02-03KURA-0.1916.6012.48
2025-02-04KURA-0.1916.6012.48
2025-02-05KURA-0.1916.6012.48
2025-02-06KURA-0.1916.6012.48
2025-02-07KURA-0.1916.6012.48
2025-02-10KURA-0.1925.2512.48
2025-02-11KURA-0.1925.2512.48
2025-02-12KURA-0.1925.2512.38
2025-02-13KURA-0.1925.2512.38
2025-02-14KURA-0.1925.2512.38
2025-02-18KURA-0.1926.6811.43
2025-02-19KURA-0.3626.6811.32
2025-02-20KURA-0.3626.6811.32
2025-02-21KURA-0.4326.6811.16
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

-0.63

Avg. EPS Est. Current Quarter

-0.64

Avg. EPS Est. Next Quarter

-0.51

Insider Transactions

-0.43

Institutional Transactions

26.68

Beta

0.84

Average Sales Estimate Current Quarter

57

Average Sales Estimate Next Quarter

10

Fair Value

Quality Score

15

Growth Score

25

Sentiment Score

32

Actual DrawDown %

80.8

Max Drawdown 5-Year %

-82.7

Target Price

27.69

P/E

Forward P/E

PEG

P/S

P/B

1.51

P/Free Cash Flow

EPS

-2.36

Average EPS Est. Cur. Y​

-2.41

EPS Next Y. (Est.)

-1.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.44

Return on Equity vs Sector %

-65.9

Return on Equity vs Industry %

-50.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

-71.5
Kura Oncology, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 142
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
stock quote shares KURA – Kura Oncology, Inc. Stock Price stock today
news today KURA – Kura Oncology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KURA – Kura Oncology, Inc. yahoo finance google finance
stock history KURA – Kura Oncology, Inc. invest stock market
stock prices KURA premarket after hours
ticker KURA fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Facebook-f Twitter Tiktok Instagram Youtube

Get Started

About